Tofacitinib versus méthotrexate en tant qu'antirhumatismal modificateur de la maladie de première intention dans le traitement de la polyarthrite rhumatoïde: Essai contrôlé randomisé en ouvert
Int J Rheum Dis. 2023;26(9):1729–1736 doi: 10.1111/1756-185X.14801
This single-centre study by Khan, et al. suggests that high-dose methotrexate (25 mg/week, subcutaneously) may be as efficacious as tofacitinib in patients with established RA who are DMARD naïve or have not received a therapeutic dose of DMARDs.